NCT00964262View on ClinicalTrials.gov

A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

SR Exenatide (PT302)

0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection

DRUG

Placebo

Plcacebo of each doasage, single subcutanoeus injection

Trial Locations (1)

110-744

Clinical Trials Center, Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Peptron, Inc.
All Listed Sponsors
lead

Peptron, Inc.

INDUSTRY